Semaglutide 12mg Auto-Injector Pen

Please note: This item is shipped directly from the manufacturer. Delivery may take slightly longer than usual, with an estimated turnaround time of 5 to 7 working days.

Novo-Lela Semaglutide 12mg Auto-Injector Pen contains a higher concentration of Semaglutide, a GLP-1 receptor agonist used in the treatment of type 2 diabetes. It functions by mimicking human glucagon-like peptide-1 to stimulate insulin release in a glucose-dependent manner, suppress glucagon secretion, and slow gastric emptying.

The 12mg Auto-Injector Pen provides the same mechanism of action and clinical benefits as the 4mg version but allows for extended use or higher maintenance doses in patients requiring intensified therapy. It offers convenient, prefilled, once-weekly administration for seamless integration into diabetes and weight management regimens.

Benefits of Semaglutide:

• Blood Sugar Regulation: Supports insulin secretion and glucagon suppression for stable glycaemic control.

• Weight Loss Support: Reduces appetite and slows gastric emptying, promoting sustainable weight reduction.

• Cardiovascular Protection: May lower the risk of major cardiovascular events in individuals with type 2 diabetes.

Dosage Instructions:

Administered subcutaneously once per week, using the prefilled Auto-Injector Pen.

• Type 2 Diabetes: Initiate at 0.25 mg weekly for four weeks, then titrate upwards to 0.5 mg, 1.0 mg, or higher as needed, depending on patient tolerance and treatment objectives.

• Weight Management: Higher maintenance doses, up to 2.4 mg weekly, may be prescribed under medical supervision.

• Injections should be administered on the same day each week, regardless of meals.

Follow the guidance of a qualified healthcare professional for dose escalation and maintenance.

Side Effects:

Side effects mirror those observed with other Semaglutide formulations:

• Gastrointestinal symptoms (nausea, vomiting, diarrhea)

• Possible hypoglycemia when combined with other therapies

• Injection site reactions

• Rare pancreatitis

• Possible gallbladder effects with prolonged use

Discuss any concerns with a healthcare provider before starting therapy.

Half-life:

Semaglutide has a half-life of approximately one week, allowing for once-weekly administration and stable therapeutic effect.

In summary, Novo-Lela Semaglutide 12mg Auto-Injector Pen offers a higher-strength formulation for patients requiring intensified treatment. It delivers the same clinically proven benefits in blood sugar regulation, weight loss, and cardiovascular protection, with the ease of a prefilled pen.